Artemis Therapeutics Inc. (ATMS)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Artemis Therapeutics Inc. (ATMS) with AI Score 51/100 (Hold). Artemis Therapeutics Inc. is a shell company with no significant operations, previously involved in developing agents for infectious diseases. Market cap: 0, Sector: Financial services.
Last analyzed: Mar 18, 2026Artemis Therapeutics Inc. (ATMS) Financial Services Profile
Artemis Therapeutics Inc., a shell company in the financial services sector, lacks significant ongoing operations after previously focusing on infectious disease treatments. Based in New York, the company's current financial metrics, including a negative P/E ratio of -21032.59 and a negative profit margin of -434.4%, reflect its dormant status.
Investment Thesis
Investing in Artemis Therapeutics Inc. (ATMS) presents a highly speculative scenario given its status as a shell company with no significant operations. The company's negative P/E ratio of -21032.59 and a profit margin of -434.4% underscore its financial challenges. Any investment would rely on potential future acquisitions or a strategic pivot that could revitalize the company. The low market capitalization of $0.06 billion reflects the market's current valuation of its limited assets and future prospects. Growth catalysts are contingent on identifying new business opportunities or undergoing a reverse merger. Investors should carefully assess the risks associated with OTC-traded shell companies before considering an investment in ATMS.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.06 billion, indicating a small valuation.
- P/E ratio of -21032.59, reflecting losses and minimal earnings.
- Negative profit margin of -434.4%, highlighting significant operational losses.
- Gross margin of 82.6%, which may be related to legacy assets or discontinued operations.
- No dividend yield, consistent with the company's lack of profitability and operational activity.
Competitors & Peers
Strengths
- Existing corporate structure
- Publicly listed status
- Potential for reverse merger
- Subsidiary of Tonak Ltd.
Weaknesses
- No significant operations
- Negative profitability
- Limited assets
- OTC listing
Catalysts
- Upcoming: Potential reverse merger with a private company.
- Upcoming: Possible acquisition by another company.
- Ongoing: Exploration of strategic alternatives.
- Ongoing: Management of existing assets.
Risks
- Potential: Failure to identify viable business opportunities.
- Potential: Regulatory scrutiny of shell companies.
- Ongoing: Limited liquidity due to OTC listing.
- Ongoing: Lack of financial transparency.
- Ongoing: Negative profitability.
Growth Opportunities
- Reverse Merger: Artemis Therapeutics could pursue a reverse merger with a private company seeking to go public without the traditional IPO process. The target company would acquire Artemis, effectively gaining a public listing. The timeline for such a transaction is highly variable, depending on finding a suitable target and completing due diligence, but can typically be completed within 6-12 months. The market for reverse mergers is substantial, offering a potentially quick route to public markets for private entities.
- Acquisition Target: Artemis Therapeutics could be acquired by another company seeking to utilize its existing corporate structure and any remaining assets. This could provide a return to shareholders through a buyout. The timeline for an acquisition depends on identifying a suitable acquirer and negotiating terms, potentially occurring within the next 12-24 months. The market for corporate acquisitions is broad, influenced by strategic consolidation and market dynamics.
- Strategic Pivot: Artemis Therapeutics could shift its business focus to a new sector, leveraging its existing corporate structure. This would require significant investment and strategic planning. The timeline for a successful pivot could extend over several years, requiring substantial capital and operational adjustments. The success of such a pivot depends on identifying a viable market opportunity and building a competitive advantage.
- Asset Monetization: Artemis Therapeutics could monetize its remaining assets, if any, to generate cash flow. This might involve selling intellectual property or other holdings. The timeline for asset monetization can vary, depending on the nature of the assets and market conditions, potentially occurring within the next 6-12 months. The market for asset sales is influenced by prevailing economic conditions and buyer demand.
- Capital Raise: Artemis Therapeutics could attempt to raise capital to fund new ventures or acquisitions. This would require convincing investors of the company's potential for future growth. The timeline for a successful capital raise depends on market conditions and investor sentiment, potentially taking several months to complete. The availability of capital is influenced by macroeconomic factors and investor risk appetite.
Opportunities
- Reverse merger with a private company
- Acquisition by another company
- Strategic pivot to a new sector
- Monetization of remaining assets
Threats
- Regulatory scrutiny of shell companies
- Market volatility
- Competition from other shell companies
- Failure to identify viable business opportunities
Competitive Advantages
- Currently, Artemis Therapeutics does not possess a significant economic moat.
- Historically, the company aimed to develop a moat through proprietary therapeutic agents.
- Any future moat would depend on the company's ability to innovate and create competitive advantages in a new market.
About ATMS
Artemis Therapeutics Inc., based in New York, operates primarily as a shell company, currently without significant business operations. Historically, the company focused on the development of therapeutic agents aimed at preventing and treating severe and life-threatening infectious diseases. However, this activity has ceased, and the company now exists as a subsidiary of Tonak Ltd., with minimal operational footprint. Founded with the intention of addressing critical needs in infectious disease management, Artemis Therapeutics aimed to create innovative solutions for a global health challenge. The company's transition to a shell corporation reflects a strategic shift away from its original focus, leaving it with a small team managing its limited assets and obligations. Artemis Therapeutics' current market position is characterized by its lack of active product development or revenue generation, making it distinct from other entities in the financial services sector.
What They Do
- Currently, Artemis Therapeutics Inc. operates as a shell company.
- Previously, the company was involved in developing agents for infectious diseases.
- The company is based in New York, New York.
- Artemis Therapeutics Inc. is a subsidiary of Tonak Ltd.
- The company has minimal ongoing business operations.
- It explores potential opportunities for reverse mergers or acquisitions.
Business Model
- Currently, Artemis Therapeutics Inc. does not have an active business model.
- Historically, the company aimed to generate revenue through the development and commercialization of infectious disease treatments.
- Future revenue generation is contingent on identifying new business opportunities or undergoing a strategic pivot.
Industry Context
Artemis Therapeutics Inc. operates within the shell company segment of the financial services industry. These companies are often characterized by minimal operations and are frequently used for reverse mergers or acquisitions. The market for shell companies is driven by entities seeking expedited access to public markets. The competitive landscape includes other shell companies like AOAO, BHAC, CLOE, IRAA, and JMTM, all vying for similar opportunities. The industry is subject to regulatory scrutiny due to the potential for misuse, requiring careful due diligence and compliance.
Key Customers
- Historically, Artemis Therapeutics targeted healthcare providers and patients needing infectious disease treatments.
- Currently, the company does not have active customers.
- Potential future customers would depend on the company's new business direction.
Financials
Chart & Info
Artemis Therapeutics Inc. (ATMS) stock price: Price data unavailable
Latest News
-
Stocks That Hit 52-Week Lows On Wednesday
· Dec 18, 2019
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ATMS.
Price Targets
Wall Street price target analysis for ATMS.
MoonshotScore
What does this score mean?
The MoonshotScore rates ATMS's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Classification
Industry Shell CompaniesLeadership: Shimon Citron
Managing Director
Shimon Citron serves as the Managing Director of Artemis Therapeutics Inc., overseeing a small team. His background includes experience in managing companies with limited operations and exploring strategic alternatives. He is responsible for guiding the company's direction and ensuring compliance with regulatory requirements. His expertise lies in corporate governance and strategic planning for companies in transition.
Track Record: Under Shimon Citron's leadership, Artemis Therapeutics has focused on maintaining its corporate structure and exploring potential opportunities for a reverse merger or acquisition. He has overseen the management of the company's limited assets and navigated the challenges of operating as a shell company. His tenure has been marked by a focus on strategic planning and compliance.
ATMS OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Artemis Therapeutics Inc. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier are often subject to less stringent regulations and may have limited trading activity. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies do not have to meet specific listing requirements, which can result in higher risk for investors.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited liquidity due to OTC listing
- Lack of financial transparency
- Potential for price manipulation
- Regulatory scrutiny of shell companies
- Uncertainty regarding future business direction
- Verify the availability of financial reports and disclosures.
- Assess the company's management team and their track record.
- Evaluate the potential for a reverse merger or acquisition.
- Understand the risks associated with OTC-traded shell companies.
- Review the company's legal and regulatory compliance.
- Check for any outstanding legal issues or liabilities.
- Assess the company's ownership structure and control.
- Subsidiary of Tonak Ltd.
- Existing corporate structure
- Publicly listed status
- Management team in place
Artemis Therapeutics Inc. Stock: Key Questions Answered
What does Artemis Therapeutics Inc. do?
Artemis Therapeutics Inc. currently operates as a shell company with no significant ongoing business operations. Previously, the company was involved in the development of agents for the prevention and treatment of severe and life-threatening infectious diseases. However, this activity has ceased, and the company is now focused on exploring potential opportunities for a reverse merger, acquisition, or strategic pivot. Its primary function is to maintain its corporate structure and evaluate potential future business directions.
What do analysts say about ATMS stock?
Given Artemis Therapeutics Inc.'s status as a shell company with limited operations, there is minimal analyst coverage. Key valuation metrics such as the negative P/E ratio of -21032.59 and a profit margin of -434.4% reflect its current financial challenges. Growth considerations are contingent on identifying new business opportunities or undergoing a strategic transformation. Investors should conduct thorough due diligence and carefully assess the risks associated with OTC-traded shell companies.
What are the main risks for ATMS?
The main risks for Artemis Therapeutics Inc. include its limited liquidity due to its OTC listing, lack of financial transparency, and potential for price manipulation. As a shell company, it faces regulatory scrutiny and uncertainty regarding its future business direction. The company's negative profitability and lack of significant operations pose additional challenges. Investors should be aware of these risks and conduct thorough due diligence before considering an investment in ATMS.
What are the key factors to evaluate for ATMS?
Artemis Therapeutics Inc. (ATMS) currently holds an AI score of 51/100, indicating moderate score. Key strength: Existing corporate structure. Primary risk to monitor: Potential: Failure to identify viable business opportunities.. This is not financial advice.
How frequently does ATMS data refresh on this page?
ATMS prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ATMS's recent stock price performance?
Recent price movement in Artemis Therapeutics Inc. (ATMS) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Existing corporate structure. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider ATMS overvalued or undervalued right now?
Determining whether Artemis Therapeutics Inc. (ATMS) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying ATMS?
Before investing in Artemis Therapeutics Inc. (ATMS), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be limited or delayed.